Recent Updates
Recently added Catalysts

Human Glucocerebrosidase

Phase 1

Gaucher Disease | Small molecule | Metabolic |Protalix BioTherapeutics, Inc. (DE)|Last Updated: Dec 4, 2006

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment6
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00258778Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)PHASE1 COMPLETED 6Nov 1, 2005Jan 1, 2006Dec 4, 2006 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
Human Glucocerebrosidase (prGCD)DRUG -
Unlock Study Design Details